Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Torti

Showing results (161-170 of 263) with videos related to

Pageof 27
Sort By:
BMJ Public Health|June 25, 2026
Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemicAndrea Carbone, Francesca Lombardi, Giorgio Tiecco, et al.
AIDS Patient Care and Stds|March 3, 2007
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros-Roldan, Carlo Torti, Giuseppe Lapadula, et al.
Journal of Infection and Public Health|September 10, 2024
Seroprevalence and age-related susceptibility of TORCH infections in childbearing age women: A 5-year cross-sectional retrospective study and a literature reviewGrazia Pavia, Francesca Licata, Nadia Marascio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcomeMassimo Puoti, Carlo Torti, Diego Ripamonti, et al.
Diagnostic Microbiology and Infectious Disease|June 29, 2018
Depression of lymphocyte activity during cutaneous leishmaniasis: a case reportGiovanni Matera, Carlo Torti, Maria Mazzitelli, et al.
The Journal of Infectious Diseases|July 11, 2003
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patientsCarlo Torti, Eugenia Quiros-Roldan, Wilco Keulen, et al.
AIDS (London, England)|October 17, 2018
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapyAnna Schultze, Carlo Torti, Alessandro Cozzi-Lepri, et al.
BMC Infectious Diseases|January 27, 2011
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti, Antonella d'Arminio-Monforte, Anton L Pozniak, et al.
Minerva Medica|April 29, 2021
Changing epidemiology of hepatitis C in Italy: a population-based survey in a historically high endemic areaEnea Spada, Cinzia Marcantonio, Maria F Vescio, et al.
Frontiers in Cellular and Infection Microbiology|January 23, 2023
Omic insights into various ceftazidime-avibactam-resistant <i>Klebsiella pneumoniae</i> isolates from two southern Italian regionsDafne Bongiorno, Dalida A Bivona, Claudia Cicino, et al.
Pageof 27

Showing results (161-170 of 263) with videos related to

Sort By:
Pageof 27
BMJ Public Health|June 25, 2026
Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemicAndrea Carbone, Francesca Lombardi, Giorgio Tiecco, et al.
AIDS Patient Care and Stds|March 3, 2007
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros-Roldan, Carlo Torti, Giuseppe Lapadula, et al.
Journal of Infection and Public Health|September 10, 2024
Seroprevalence and age-related susceptibility of TORCH infections in childbearing age women: A 5-year cross-sectional retrospective study and a literature reviewGrazia Pavia, Francesca Licata, Nadia Marascio, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcomeMassimo Puoti, Carlo Torti, Diego Ripamonti, et al.
Diagnostic Microbiology and Infectious Disease|June 29, 2018
Depression of lymphocyte activity during cutaneous leishmaniasis: a case reportGiovanni Matera, Carlo Torti, Maria Mazzitelli, et al.
The Journal of Infectious Diseases|July 11, 2003
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patientsCarlo Torti, Eugenia Quiros-Roldan, Wilco Keulen, et al.
AIDS (London, England)|October 17, 2018
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapyAnna Schultze, Carlo Torti, Alessandro Cozzi-Lepri, et al.
BMC Infectious Diseases|January 27, 2011
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti, Antonella d'Arminio-Monforte, Anton L Pozniak, et al.
Minerva Medica|April 29, 2021
Changing epidemiology of hepatitis C in Italy: a population-based survey in a historically high endemic areaEnea Spada, Cinzia Marcantonio, Maria F Vescio, et al.
Frontiers in Cellular and Infection Microbiology|January 23, 2023
Omic insights into various ceftazidime-avibactam-resistant <i>Klebsiella pneumoniae</i> isolates from two southern Italian regionsDafne Bongiorno, Dalida A Bivona, Claudia Cicino, et al.
Pageof 27